dirucotide also known developed two research scientists dr kenneth g warren md frcpc ingrid catz senior scientist university alberta treatment multiple sclerosis ms dirucotide synthetic peptide consists amino acids linked sequence identical portion human myelin basic protein mbp sequence amino acids results phase ii longterm followup trial showed dirucotide safely delayed median time disease progression five years progressive ms patients immune response genes seem effective patients gene drug exclusively licensed bioms medical corp canadianbased biotechnology company bioms medical received clearance food drug administration fda initiate phase iii clinical trial named secondary progressive ms patients january additional phase iii clinical trial dirucotide undertaken canada europe september drug granted fda fasttrack phase ii trial dirucotide potential therapy relapsingremitting multiple sclerosis rrms failed achieve primary endpoint reduced relapse rate reduce new mri lesions however reduce progression expanded disability status scale edss multiple sclerosis functional composite msfc scale phase iii trials progress reduction edss msfc progression primary bioms medical agreed share development dirucotide eli lilly company received exclusive worldwide rights future research development manufacturing marketing cells producing receptors recognizing mbp fragments presented mhc molecules antigen presenting cells seem play role pathogenesis ms repeated application dirucotide intravenous every six months represses immunological response july statement released stating bioms medical corp tsx ms today announced dirucotide meet primary endpoint delaying disease progression measured expanded disability status scale edss twoyear phase iii trial patients secondary progressive multiple sclerosis spms addition statistically significant differences dirucotide placebo secondary endpoints study means trials discontinued httpsenwikipediaorgwikidirucotide